MEsenchymal StEm cells for Multiple Sclerosis (MESEMS) study: Results from a multi-center, randomized, double blind, cross-over phase 2 clinical trial with autologous Mesenchymal Stem Cells (MSC) for the therapy of multiple sclerosis

Authors
Category Primary study
JournalEuropean Journal of Neurology
Year 2020
This article has no abstract
Epistemonikos ID: 9452dc35fd36c505046bd183edfb98ca6c36e56f
First added on: Mar 31, 2022